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Abstract
Dysferlin is a multi-C2 domain transmembrane protein involved in a plethora of cellular functions, most notably in skeletal
muscle membrane repair, but also in myogenesis, cellular adhesion and intercellular calcium signaling. We previously
showed that dysferlin interacts with alpha-tubulin and microtubules in muscle cells. Microtubules are heavily reorganized
during myogenesis to sustain growth and elongation of the nascent muscle fiber. Microtubule function is regulated by post-
translational modifications, such as acetylation of its alpha-tubulin subunit, which is modulated by the histone deacetylase 6
(HDAC6) enzyme. In this study, we identified HDAC6 as a novel dysferlin-binding partner. Dysferlin prevents HDAC6 from
deacetylating alpha-tubulin by physically binding to both the enzyme, via its C2D domain, and to the substrate, alpha-
tubulin, via its C2A and C2B domains. We further show that dysferlin expression promotes alpha-tubulin acetylation, as well
as increased microtubule resistance to, and recovery from, Nocodazole- and cold-induced depolymerization. By selectively
inhibiting HDAC6 using Tubastatin A, we demonstrate that myotube formation was impaired when alpha-tubulin was
hyperacetylated early in the myogenic process; however, myotube elongation occurred when alpha-tubulin was
hyperacetylated in myotubes. This study suggests a novel role for dysferlin in myogenesis and identifies HDAC6 as a novel
dysferlin-interacting protein.
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Introduction
Recessive mutations in the DYSF gene cause Limb girdle
muscular dystrophy type 2B (LGMD2B) [1], Miyoshi Myopathy
[1] and Distal anterior compartment myopathy [2]. Dysferlin is a
large type II transmembrane protein composed of two DysF
domains and seven C2 domains that mediate lipid [3,4] and
protein binding interactions [5,6,7,8,9]. Dysferlin is predominantly
expressed in skeletal and cardiac muscle [10], and its expression is
upregulated during myogenesis [11,12]. The subcellular localiza-
tion of dysferlin is at the sarcolemma, T-tubule membranes and
in intracellular vesicular compartments of as yet unknown origin
[13,14]. Dysferlin is a critical component of the calcium-dependent
sarcolemmal repair complex, but recent studies have proposed
additional roles for dysferlin in myogenesis [15,16,17], intercellular
calcium signaling [18] and cellular adhesion [19]. Our recent work
identified alpha-tubulin and microtubules as novel binding partners
of dysferlin [6], suggesting a possible role for dysferlin in
microtubule dynamics or stability.
The upregulation of microtubule acetylation is essential for
myogenesis [20]. Microtubule acetylation is regulated by alpha-
tubulin acetyltransferases and deacetylases, the most notable one
being histone deacetylase 6 (HDAC6) [21]. Unlike most classical
HDACs which are located in the nucleus and deacetylate nuclear
substrates such as histones, HDAC6 contains a nuclear exclusion
signal and a cytoplasmic retention signal making it a cytoplasmic
enzyme [21,22]. HDAC6 has two catalytic hdac domains used to
deacetylate alpha-tubulin [21,23,24], cortactin [23,25,26] and
Hsp90 [27]. HDAC6-mediated microtubule deacetylation plays
important regulatory roles in microtubule dynamics [28,29],
cellular motility [23,26,30,31] and motor protein motility [32].
In this study, we identified HDAC6 as a novel dysferlin
interacting protein. Our results revealed that dysferlin binds to
HDAC6 and alpha-tubulin, and prevents HDAC6 from deacety-
lating its substrate, alpha-tubulin. We also demonstrated that
inhibition of HDAC6 activity in the early stages of myoblast
differentiation results in impaired myogenesis, whereas increased
microtubule acetylation in myotubes results in myotube elonga-
tion. We suggest that the increasing dysferlin expression observed
during myogenesis could be required to decrease HDAC6-
mediated microtubule deacetylation.
Results
Dysferlin interacts with HDAC6 and prevents alpha-
tubulin deacetylation
We had previously performed a mass spectrometric analysis of
the dysferlin protein complex [6] and identified HDAC6 as a
potential dysferlin interactor. This protein was also identified in
another study [33]. To confirm this interaction, we performed
binding assays using recombinant and native dysferlin and
HDAC6 proteins. Recombinant dysferlin was able to bind either
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(Figure 1A) or to native HDAC6 from homogenized murine testes
(Figure 1B), which are a rich source of the enzyme. Co-
immunoprecipitation assays performed in mouse skeletal muscle
extracts showed that native dysferlin co-immunoprecipitated with
native HDAC6 (Figure 1C).
To determine if dysferlin and HDAC6 co-localized in the same
subcellular compartment, GFP-myc-dysferlin and FLAG-HDAC6
were transfected into Cos7 cells. Immunostaining showed partial
co-localization between the two proteins in the cytoplasm and in
the vicinity of the plasma membrane (Figure 1D). To determine if
the proteins co-localized in muscle cells, FLAG-HDAC6 was
transfected into a human myoblast cell line (134/04), which
harbours two wildtype DYSF alleles, and cells were differentiated
into myotubes. Immunostaining with anti-dysferlin and anti-
FLAG antibodies demonstrated that the proteins partially co-
localized in the cytoplasm and in the vicinity of the plasma
membrane (Figure 1E).
To identify which of dysferlin’s seven C2 domains could be
involved in the interaction with HDAC6, we constructed a series
of single C2 domain deletion mutants from full-length wildtype
(WT) dysferlin, which harbours an N-terminal GFP tag and C-
terminal myc-His tags (Figure 2A). Each mutant (DC2A to DC2G),
or WT dysferlin or a GFP vector was expressed in HEK293T cells,
immobilized on nickel affinity beads, and incubated either with
recombinant FLAG-HDAC6 (Figure 2B) or with native HDAC6
from homogenized murine testes (Figure 2C). In both assays,
dysferlin’s C2D domain was required for the interaction with
HDAC6.
Given that HDAC6 is a major alpha-tubulin deacetylase, we
assayed for dysferlin’s effect on alpha-tubulin acetylation. Alpha-
tubulin acetylation levels increased in HEK293T cells expressing
wildtype dysferlin (WT) or the following C2 domain deletion
mutants: DC2B, DC2C, DC2E, DC2F and DC2G (Figure 2D).
Cells expressing DC2A or DC2D showed no change in alpha-
tubulin acetylation levels compared to GFP vector-expressing cells,
Figure 1. Dysferlin co-immunoprecipitates with HDAC6. (A) HEK293T cells were transfected with GFP-myc-dysferlin (GFP-myc-Dysf) and FLAG-
HDAC6, and recombinant dysferlin was immunoprecipitated (IP) with anti-myc antibodies. Immunoprecipitates were separated by SDS-PAGE and
immunoblotted (IB) with the indicated antibodies. SM=starting material, 5% of total protein loaded. (B) GFP-myc-dysferlin (GFP-myc-Dysf) or GFP
vector were transfected in HEK293T cells, immunoprecipitated with anti-GFP antibodies and incubated with testes homogenate from wildtype C57Bl/
6 mice, which is a rich source of HDAC6. Immunoprecipitates were immunoblotted with the indicated antibodies. Alpha-tubulin was used as a
loading control. (Right panel) HDAC6 protein levels in testes of wildtype C57Bl/6 mice (WT) versus HDAC6 knockout mice (KO), which were
immunoblotted with anti-HDAC6 antibodies to demonstrate the specificity of the detected band. (C) Native dysferlin was immunoprecipitated with
anti-dysferlin antibodies in mouse skeletal muscle extracts. Immunoprecipitates were separated by SDS-PAGE and immunoblotted with anti-dysferlin
and anti-HDAC6 antibodies. (D) GFP-myc-dysferlin and FLAG-HDAC6 were overexpressed in Cos7 cells. Cells were fixed and immunostained with anti-
GFP and anti-FLAG antibodies. (E) 134/04 cells were transfected with FLAG-HDAC6 and differentiated into myotubes. Cells were fixed and
immunostained with anti-dysferlin and anti-FLAG antibodies. Scale bar: 20 mm.
doi:10.1371/journal.pone.0028563.g001
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domain deletion constructs. (B) Wildtype dysferlin (WT), dysferlin deletion mutants (DC2A through DC2G) or GFP vector were transfected in HEK293T
cells, pulled-down on Ni-NTA beads, and incubated with FLAG-HDAC6-transfected HEK293T cell lysates. Immunoprecipitates were immunoblotted
with the indicated antibodies. (Right panel) FLAG-HDAC6 expression levels in transfected HEK293T cell lysates, immunoblotted with anti-FLAG
antibody. (C) Wildtype dysferlin (WT), dysferlin deletion mutants (DC2A through DC2G) or GFP vector were transfected in HEK293T cells, pulled-down
on Ni-NTA beads, and incubated with murine testes homogenate. Immunoprecipitates were immunoblotted with the indicated antibodies. (Right
panel) This western blot is identical to the one displayed in Fig. 1B. (D) Cell lysates from (C) were immunoblotted for alpha-tubulin acetylation levels.
Similar results observed with cell lysates from (B) (not shown).
doi:10.1371/journal.pone.0028563.g002
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prevent HDAC6 from deacetylating alpha-tubulin.
Dysferlin requires alpha-tubulin binding to prevent
HDAC6 from deacetylating alpha-tubulin
We recently showed that dysferlin interacts with alpha-tubulin
through its C2A and C2B domains, although this interaction is
weaker with the C2B domain than with the C2A domain [6].
Figures 2B and 2C show that the DC2A deletion mutant
interacted less strongly with alpha-tubulin when compared to
wildtype dysferlin or the other six deletion mutants, which is in
agreement with our previously published results. Notably, the
interaction was not fully abolished since the DC2A deletion
mutant retains its C2B domain, which also interacts with alpha-
tubulin, albeit weakly. Theorizing that dysferlin requires both of its
alpha-tubulin binding domains to interact with HDAC6, we used
a truncated dysferlin mutant lacking its three N-terminal C2
domains, but retaining its DysF domains (DD) and the
transmembrane domain (TM) (DD-DEFG-TM) (Figure 3A). As
expected, this N-terminally truncated mutant did not pull down
alpha-tubulin, and also showed weaker binding to HDAC6
(Figure 3B). This suggests that dysferlin also requires both of its
alpha-tubulin binding domains (C2A and C2B) to fully interact
with HDAC6.
We assessed whether the truncated mutant DD-DEFG-TM
could affect alpha-tubulin acetylation levels in HEK293T cells. As
shown in Figure 3C, DD-DEFG-TM did not alter the amount of
acetylated alpha-tubulin, similarly to DC2A and DC2D deletion
mutants. In agreement with Figure 2D, these results highlight the
importance of dysferlin’s C2A domain in preventing alpha-tubulin
deacetylation.
Having shown that dysferlin’s alpha-tubulin binding domains
are important for impairing HDAC6-mediated deacetylation of
alpha-tubulin, we theorized that dysferlin may be having this effect
by affecting HDAC6’s ability to interact with its substrate. To
assess how dysferlin may affect HDAC6’s interaction with alpha-
tubulin, we performed an alpha-tubulin immunoprecipitation
assay in HEK293T cells expressing FLAG-HDAC6 along with
either wildtype dysferlin (WT), the DC2A or DC2D deletion
mutants, or with the truncated mutant (DD-DEFG-TM). As
shown in Figure 3D, in the absence of dysferlin, HDAC6 is able to
bind to alpha-tubulin. However, in the presence of full-length
dysferlin, alpha-tubulin no longer pulled down HDAC6, but only
dysferlin. This effect was only observed if dysferlin retained its
C2D domain as well as its alpha-tubulin binding C2A and C2B
domains; if these domains were deleted, dysferlin did not prevent
HDAC6 from interacting with alpha-tubulin. This is demonstrated
by the DC2D and DD-DEFG-TM constructs, which showed an
unimpaired HDAC6 interaction with alpha-tubulin (Figure 3D).
Because the DC2A construct still had partial alpha-tubulin binding
capabilities and an intact C2D domain, it was able to decrease
HDAC6’s interaction with alpha-tubulin, but not abolish it
completely as did wildtype dysferlin. These results suggest that
dysferlin prevents HDAC6 from interacting with its substrate, thus
hindering alpha-tubulin deacetylation.
Dysferlin expression increases alpha-tubulin acetylation
and resistance to microtubule depolymerization
Having demonstrated that recombinant dysferlin affects alpha-
tubulin acetylation levels in HEK293T cells, we assessed whether
native dysferlin expression also affected alpha-tubulin acetylation
in muscle cells. We used three human myoblast cell lines: 134/04
cells harbouring two wildtype DYSF alleles, ULM1/01 cells
harbouring twononsenseDYSFalleles,and180/06 cellsharbouring
one missense DYSF allele and one nonsense DYSF allele. The cells
were cultured, lysed and immunoblotted for acetylated-alpha-
tubulin and alpha-tubulin levels. As shown in Figure 4A, wildtype
Figure 3. Dysferlin requires its alpha-tubulin binding domains
to bind HDAC6 and prevent alpha-tubulin deacetylation. (A)
Schematic of dysferlin truncation construct (DD-DEFG-TM). (B) Wildtype
dysferlin (WT), dysferlin deletion mutants DC2A and DC2D, or DD-DEFG-
TM were transfected in HEK293T cells, pulled-down on Ni-NTA beads,
incubated with murine testes homogenate and immunoblotted with
the indicated antibodies. (C) Cell lysates from (B) were immunoblotted
for alpha-tubulin acetylation levels. (D) FLAG-HDAC6 was co-transfected
with wildtype dysferlin (WT), dysferlin deletion mutants (DC2A and
DC2D), dysferlin truncation (DD-DEFG-TM) or GFP vector in HEK293T
cells, immunoprecipitated with anti-alpha-tubulin antibodies, and
immunoblotted with the indicated antibodies. As controls, cell lysates
were immunoprecipitated without antibodies (CTL) or with anti-IgG
antibodies (IgG).
doi:10.1371/journal.pone.0028563.g003
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dysferlin-deficientcells(180/06 andULM1/01).Toconfirmthat the
effect was specific to dysferlin expression, wildtype dysferlin (WT) or
the DC2A deletion mutant was overexpressed in 134/04 cells. In
agreement with Figures 2D and 3C, dysferlin overexpression in
muscle cells resulted in increased alpha-tubulin acetylation levels,
whereas expression of the DC2A deletion mutant did not affect
alpha-tubulin acetylation (Figure 4B).
Microtubule post-translational modifications occur subsequent
to microtubule stabilization; therefore alpha-tubulin acetylation
can be considered as a marker of stabilized microtubules [34].
Stabilized microtubules are more resistant to microtubule
depolymerization. We theorized that the increased alpha-tubulin
acetylation levels observed in dysferlin-expressing cells were
indicative of a pool of microtubules with increased resistance to
depolymerization. To test this theory, we employed cold-induced
and Nocodazole-induced microtubule depolymerization assays. In
the cold-induced depolymerization assay, 134/04, 180/06 and
ULM1/01 cells were incubated at 4uC for increasing lengths of
time, and microtubule resistance was assessed by the amount of
acetylated alpha-tubulin remaining post-treatment. As shown in
Figures 5A and 5E, 134/04 cells retained significantly higher
acetylated alpha-tubulin levels following cold treatments (30, 45
and 60 min) than dysferlin-deficient 180/06 and ULM1/01 cells.
In the Nocodazole-induced depolymerization assay, 134/04, 180/
06 and ULM1/01 cells were treated with increasing concentra-
tions of Nocodazole, and microtubule resistance to depolymeriza-
tion was assessed by the amount of acetylated alpha-tubulin
remaining post-treatment. As shown in Figures 5B and 5F, 134/04
cells retained significantly higher acetylated alpha-tubulin levels
following Nocodazole treatment (3 mg/ml and 9 mg/ml) than
dysferlin-deficient 180/06 and ULM1/01 cells. To demonstrate
that the effect was specific to dysferlin expression, wildtype
dysferlin (WT) or DC2A were expressed in HEK293T cells, which
were similarly treated with Nocodazole. As shown in Figures 5C
and 5G, cells transfected with WT dysferlin showed significantly
more acetylated alpha-tubulin levels post-Nocodazole treatment
when compared to untransfected (CTL) cells. In agreement with
our previous results, this effect required dysferlin’s C2A domain, as
cells transfected with DC2A showed acetylated alpha-tubulin levels
that were comparable to untransfected (CTL) cells. These results
suggest that dysferlin expression correlates with increased
microtubule resistance to Nocodazole treatment, indicative of
the presence of a larger pool of stable microtubules.
Once the microtubule depolymerising agent is removed,
microtubules will repolymerize during a recovery phase [35]. To
study the effect of dysferlin expression on microtubule recovery
from Nocodazole treatment, cells were treated with Nocodazole
for 45 min and then the drug-containing media was removed and
replaced with fresh media, thus allowing repolymerization of
microtubules. After defined lengths of time, the alpha-tubulin
acetylation levels were measured as a marker of microtubule
repolymerization and stabilization. Figures 5D and 5H show that
dysferlin expression (134/04 cells) resulted in faster recovery from
Nocodazole treatment than was observed in dysferlin-deficient
cells (180/06 or ULM1/01 cells). Taken together, these results
show that dysferlin expression increases cellular alpha-tubulin
acetylation levels, as well as promotes microtubule resistance to,
and recovery from, induced depolymerization.
Hyperacetylation of alpha-tubulin impairs myogenesis
Microtubule acetylation and dysferlin expression are both
upregulated during myogenesis [11,20]. To demonstrate this in
our cultured human myoblasts, 134/04 cells were cultured in
differentiation media for up to four days to induce myotube
formation. Lysates from these cells and from homogenized mouse
skeletal muscle were immunoblotted for dysferlin and acetylated-
alpha-tubulin levels. Results showed that both dysferlin and
acetylated alpha-tubulin levels increased during myogenic differ-
entiation (Figure 6A). Immunofluorescent staining for acetylated
alpha-tubulin levels in 134/04 cells show significantly higher levels
in differentiated myotubes than in undifferentiated myoblasts
(Figure 6B). On the other hand, dysferlin-deficient myoblasts
(180/06) do not differentiate into myotubes and the acetylated
alpha-tubulin were unchanged even after four days in differenti-
ation media (Figure 6B).
Our data suggests that upregulated dysferlin expression would
increase microtubule acetylation via its interaction with HDAC6.
Given that microtubule acetylation is a late-stage event in myo-
genesis, we theorized that early upregulation of dysferlin would
result in prematurely increased acetylation levels, which could
have detrimental effects on myotube formation. However, dysfer-
lin has previously been shown to play a role in myogenesis [16,17],
for instance by affecting myogenin expression [16]. Therefore,
it would not be possible to attribute any potential myogenic effect
from overexpressing dysferlin in dysferlin-deficient myoblasts speci-
fically to dysferlin’s role on alpha-tubulin acetylation. Therefore, we
used instead an HDAC6-specific inhibitor that causes alpha-tubulin
hyperacetylation, to mimic the effect of dysferlin overexpression on
alpha-tubulin acetylation specifically. Tubastatin A is a more
selective derivative of the HDAC6 specific inhibitor Tubacin, which
specifically inhibits alpha-tubulin deacetylation without affecting
HDAC6’s other substrates [24,29,30,36,37].
Myoblast differentiation assays were performed by treating
134/04 human myoblasts and C2C12 murine myoblasts contin-
uously with Tubastatin A beginning at different stages of myoblast
differentiation: at the stage when myoblasts were undifferentiated
(Day 0), at the stage when myoblasts were beginning to form
Figure 4. Dysferlin expression increases alpha-tubulin acetylation in muscle cells. (A) 134/04, 180/06 and ULM1/01 cell lysates were
immunoblotted with anti-dysferlin and anti-acetylated alpha-tubulin antibodies. Alpha-tubulin was used as a loading control. (B) GFP-dysferlin
wildtype (WT) or GFP-dysferlinDC2A (DC2A) were transfected into 134/04 myoblasts. Transfected and untransfected (CTL) cell lysates were separated
by SDS-PAGE and immunoblotted with the indicated antibodies.
doi:10.1371/journal.pone.0028563.g004
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PLoS ONE | www.plosone.org 6 December 2011 | Volume 6 | Issue 12 | e28563Figure 6. Dysferlin and acetylated alpha-tubulin levels increase during differentiation. (A) 134/04 cells were cultured in differentiation
media for the indicated number of days. Cell lysates from these cells and mouse skeletal muscle extract were immunoblotted with the indicated
antibodies. (B) 134/04 cells and 180/06 cells were cultured in differentiation media for 0 days or 4 days to induce myotube formation. Cells were fixed
and immunostained with anti-acetylated alpha-tubulin antibodies and DAPI. Images were captured at the same fluorescence intensity and gain to
compare alpha-tubulin acetylation levels between cells. Scale bar: 20 mm.
doi:10.1371/journal.pone.0028563.g006
Figure 5. Dysferlin expression increases resistance to microtubule depolymerization. (A) 134/04, 180/06 and ULM1/01 cells were
incubated at 4uC for increasing lengths of time. Cell lysates were immunoblotted with the indicated antibodies. To equalize the baseline (0 min)
acetylated alpha-tubulin levels in the 180/06 and ULM1/01 cells with those of the 134/04 cells, the intensity of the bands was linearly increased post-
acquisition. (B) 134/04, 180/06 and ULM1/01 cells were untreated (Unt), mock-treated (Mock) or treated with increasing concentrations of
Nocodazole. Cell lysates were immunoblotted with the indicated antibodies. To equalize the baseline (Unt) acetylated alpha-tubulin levels in the 180/
06 and ULM1/01 cells with those of the 134/04 cells, the intensity of the bands was linearly increased post-acquisition. (C) GFP-dysferlin wildtype
(GFP-Dysf WT) or GFP-dysferlinDC2A (GFP-DysfDC2A) were transfected into HEK293T cells. Transfected and untransfected (CTL) cells were treated
with increasing concentrations of Nocodazole. Cell lysates were immunoblotted with the indicated antibodies. (D) 134/04, 180/06 and ULM1/01 cells
were untreated (Unt) or treated with 2.5 mg/ml Nocodazole, then the drug-containing media was replaced with fresh media and cells were allowed to
recover for the indicated lengths of time. Cell lysates were immunoblotted with the indicated antibodies. To equalize the baseline (Unt) acetylated
alpha-tubulin levels in the 180/06 and ULM1/01 cells with those of the 134/04 cells, the intensity of the bands was linearly increased post-acquisition.
(E, F, G) The ratio of acetylated alpha-tubulin:alpha-tubulin at each time point or Nocodazole concentration was normalized to 134/04 levels to
equalize starting values. * indicates that 134/04 values or GFP-Dysf WT values were significantly greater (p,0.05) than 180/06 and ULM1/01 levels (E,
F) or CTL and DC2A levels (G), at the indicated time point or concentration. (H) The ratio of acetylated alpha-tubulin: alpha-tubulin was calculated for
each time point and normalized to 134/04 levels to equalize starting values. *, # and+indicate that the value at the indicated time point is
significantly different (p,0.05) than the Unt value for 134/04, 180/06, ULM1/01, respectively.
doi:10.1371/journal.pone.0028563.g005
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differentiated (Day 4) (Figure 7A). Acetylated alpha-tubulin levels
in the cell lysates were assessed to confirm Tubastatin A efficacy
(Figure 7B). The cells were immunostained for desmin and DAPI
(Figure 7C). Desmin-stained myotubes were counted and catego-
rized according to length (Figure 7D). The number of nuclei per
myotube was also counted and the average number of nuclei in
each category of myotube length was determined (Figure 7E).
When treated early (Day 0, Day 2), myotube formation was
significantly impaired (Figure 7C), resulting in fewer myotubes
being formed (Figure 7F). The myotubes that did form were
significantly shorter than mock-treated myotubes; additionally no
long myotubes (.500 mm) were produced (Figure 7D). Converse-
ly, when myotubes were hyperacetylated after terminal differen-
tiation (Day 4), a significantly larger proportion of myotubes were
longer than 600 mm when compared to mock-treated cells
(Figure 7D), indicating that myotube length was increased. The
average number of nuclei in this category of myotubes (.600 mm)
was not significantly different from mock-treated cells (Figure 7E),
indicating that the increased length was not due to increased
myoblast fusion. These results suggest that microtubule hyper-
acetylation in the early-stages of myoblast differentiation is
detrimental to myogenesis, whereas late-stage hyperacetylation
can promote myotube elongation.
Discussion
Dysferlin is a multi-C2 domain transmembrane protein
involved in skeletal muscle membrane repair, and has also been
implicated in myogenesis, cellular adhesion and intercellular
calcium signaling. In light of the growing evidence supporting
dysferlin’s multifunctionality, understanding dysferlin’s biology will
depend on identifying its interacting proteins. To this end, we
previously undertook a proteomic search through the analysis of
immunoprecipitated proteins from mouse skeletal muscle using
liquid chromatography-tandem mass spectrometry [6]. In this
study, we identified HDAC6 as a novel dysferlin binding partner,
and present a new function for dysferlin in the modulation of
alpha-tubulin acetylation via an interaction with this microtubule
deacetylase.
We show that dysferlin prevents HDAC6 from deacetylating
alpha-tubulin by physically binding both to the enzyme via its
C2D domain and to the substrate, alpha-tubulin, via its alpha-
tubulin binding C2A and C2B domains. Consequently, dysferlin
expression increased the alpha-tubulin acetylation levels in muscle
cells. The increased alpha-tubulin acetylation levels in dysferlin-
expressing cells reflect a larger pool of stable microtubules, which
we showed are more resistant to Nocodazole-induced depolymer-
ization and cold-induced depolymerization. Dysferlin expression
also promoted faster microtubule recovery from depolymerization,
resulting in more microtubules being repolymerized, stabilized and
consequently post-translationally modified by acetylation.
A question that emerges from this study is how dysferlin
prevents HDAC6 from interacting with its substrate. One
possibility is that dysferlin targets HDAC6 via its C2D domain
and then reinforces the interaction by binding to alpha-tubulin.
Dysferlin may then directly or indirectly block HDAC6 from
interacting with alpha-tubulin, thus inhibiting its ability to
deacetylate microtubules. This is demonstrated by the observation
that (i) loss of dysferlin’s C2A domain resulted in a decreased
interaction between HDAC6 and alpha-tubulin (Figure 3D) and
(ii) loss of both of dysferlin’s C2A and C2B domains resulted in
decreased binding between dysferlin and HDAC6 (Figure 3B).
Another possibility is that dysferlin binds to alpha-tubulin via its
C2A and C2B domains, and uses its HDAC6-binding C2D
domain to block or dislodge the enzyme from alpha-tubulin. This
is suggested by the alpha-tubulin co-immunoprecipitation exper-
iment (Figure 3D), in which full-length dysferlin was pulled down
by alpha-tubulin but HDAC6 was not. It is further possible that
dysferlin may sequester HDAC6 away from its substrate, as
Figure 2 demonstrated a strong interaction between full-length
dysferlin and HDAC6 that may be indicative of a cytoplasmic
subpopulation of the two proteins which would not be observed in
the alpha-tubulin co-immunoprecipitation experiment. Further
studies would be required to elucidate the mechanism involved in
dysferlin’s interaction with HDAC6.
To study the effect of alpha-tubulin hyperacetylation on myo-
genesis, we used Tubastatin A, a selective HDAC6 inhibitor.
When HDAC6 was inhibited early during differentiation, myo-
tube formation was impaired, whereas HDAC6 inhibition in
differentiated myotubes promoted myotube elongation.
Impaired myogenesis arising from early microtubule hyperace-
tylation could be caused by disrupted microtubule dynamics and
protein targeting. Dynamic microtubules are required to target the
cell periphery and HDAC6 inhibition has been shown to decrease
microtubule dynamics [28,29]. Premature HDAC6 inhibition
could promote a more stabilized microtubule pool, thus impairing
the microtubule reorganization from a radial configuration in
undifferentiated myoblasts to the organized longitudinal array
observed in differentiated myotubes. Alpha-tubulin hyperacetyla-
tion would also compromise the microtubule tracks used for
protein, vesicle and organelle delivery. Proteins, such as CLASPs,
depend on spatial cues along microtubules to locally regulate
microtubule dynamics, which are provided by discrete regions of
microtubule acetylation [38]. Such signals would be disrupted by
microtubule hyperacetylation.
In myotubes, on the contrary, increased microtubule acetylation
could promote myotube elongation by affecting microtubule
polarization and motor protein movement. It has been proposed
that the linear microtubule array in differentiated myotubes
directly promotes myotube elongation by providing polarization,
which restricts myotube elongation to a single axis [39,40].
Furthermore, microtubule acetylation enhances kinesin-1 recruit-
ment to microtubules and anterograde movement along microtu-
bules [32,41], thus permitting the delivery of cytoskeletal
remodelling factors, target site recognition molecules or adhesion
molecules [42,43]. Additionally, microtubule acetylation has been
proposed to designate stabilized microtubules extending all the
way to a destination [32], thus promoting the delivery of proteins
necessary for myotube formation and elongation.
Dysferlin expression is upregulated during myogenesis, with
higher levels being observed in differentiated myotubes [11,12]. We
showed that Tubastatin A treatment of undifferentiated myoblasts
resulted in impaired myotube formation, such as is observed in
dysferlin-deficient myoblasts [16,17]. Thus, our study suggests that
early expression of dysferlin would promote premature microtubule
hyperacetylation by way of inhibiting HDAC6, which would impair
myotube formation. On the other hand, later expression of dysferlin
would promote myotube formation and elongation through
increased microtubule acetylation. This could explain the temporal
expression pattern of dysferlin during myogenesis. The observed
reduction in the number of long myotubes, and concomitant
increase in short myotubes, in dysferlin-deficient cell cultures
[15,17] is in keeping with our explanation for the temporally-
regulated dysferlin expression during myogenesis. We theorize that
the impaired myotube elongation in these cells might in part be
explained by active HDAC6, which would maintain low levels of
acetylated microtubules.
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PLoS ONE | www.plosone.org 8 December 2011 | Volume 6 | Issue 12 | e28563Figure 7. Effect of HDAC6 inhibition on myotube formation. (A) C2C12 or 134/04 myoblasts were seeded in growth media on Day -1, then
switched to differentiation media on Day 0. Cells were mock-treated (Mock) or treated with 7.5 mM Tubastatin A beginning on different days post-
induction of myogenic differentiation (Day 0, Day 2, Day 4). On Day 5, cells were fixed and stained with an anti-desmin antibody and DAPI. (B) Alpha-
tubulin acetylation levels were assayed to confirm Tubastatin A efficacy. (C) Representative immunofluorescence images of desmin-stained myotubes
in each treatment regime. Scale bar: 60 mm. (D) Desmin-stained myotubes were categorized by their myotube length, and plotted against their
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PLoS ONE | www.plosone.org 9 December 2011 | Volume 6 | Issue 12 | e28563For the design of dysferlin gene therapies, our study would
caution against the use of ubiquitous promoters or promoters
expressed early in muscle development, such as CMV and CAG
[44]. Instead our data would support the use of promoters that are
expressed at later stages of muscle differentiation, such as C5–12
[45] and the human a-skeletal actin promoter [44].
In summary, we have identified HDAC6 as a novel dysferlin-
interacting protein, and demonstrated that the interaction between
these two proteins is mediated by dysferlin’s C2D domain and that
dysferlin prevents HDAC6 from deacetylating alpha-tubulin by
physically binding to both the enzyme and to the substrate, alpha-
tubulin. Finally, we demonstrated the importance of late alpha-
tubulin hyperacetylation during the myogenic process, and
propose that dysferlin may act as an inhibitor of HDAC6-
mediated microtubule deacetylation during myogenesis.
Materials and Methods
Ethics Statement
All animals were handled in strict accordance with good animal
practice as defined by the relevant national and/or local animal
welfare bodies, and all animal work was approved by the
appropriate committee: Cantonal Veterinary Office of Basel,
Switzerland (Approval IDs: 2391 and 51). Primary human
myoblasts (134/04, 180/06 and ULM1/01) were obtained from
EuroBioBank (www.eurobiobank.org) along with the required
regulatory permissions (Approval ID: LMU 107/01).
Cell Cultures
C2C12 murine myoblasts and Human embryonic kidney derived
cells (HEK293T) were purchased from ATCC (Burlington, Ontario)
(ATCC number CRL-1573 and CRL-1772 respectively) [6]. 134/
04cells containtwowildtype DYSF alleles;180/06cellsharbourone
DYSFallelecontaining themissense mutation C1663T(Arg555Trp)
and an additional null allele 3708delA (D1237TfsX24). Myoblast
culture ULM1/01 harbours two null alleles: a C4819T (R1607X)
substitution and a 5085delT (F1695LfsX48) deletion. Myoblast
cultures wereimmortalized with a retrovirus carryingthe E6E7early
region from human papillomavirus type 16, as previously described
[46]. Cells were maintained in growth media (10% FBS (Gibco) in
DMEM (Sigma)).
Plasmids, Constructs, Antibodies
FLAG-tagged HDAC6 was purchased from AddGene (Plasmid
number 13823). The GFP-myc-His-Dysferlin was a kind gift from
Dr. K. Bushby, Newcastle [6,47]. GFP-tagged dysferlin C2-domain
deletion mutants were cloned from the full-length dysferlin
construct, each having a single C2 domain deleted. Deletion of
the C2 domains coding region was performed by PCR mutagenesis
using domain spanning oligonucleotides and the QuikChange Site-
Directed Mutagenesis Kit (Stratagene), using either the single [48]
or double mutagenic primers approach (Supplementary Table S1).
The procedure was performed according to the manufacturer’s
protocols. Dysferlin truncation construct (DD-DEFG-TM), retain-
ing its DysF domains (DD) and C2D-E-F-G domains (DEFG) and
transmembrane domain (TM), was cloned from the full-length
dysferlin construct. The C-terminal DD-DEFG-TM portion was
first cloned into the pcDNA/TO/myc-His vector (Invitrogen), and
then eGFP was added N-terminally in a second cloning step
(Supplementary Table S1). All clones were sequenced in both DNA
strands to confirm the deletions and the conservation of the reading
frame.
Mouse monoclonal antibodies against dysferlin, FLAG and
acetylated alpha-tubulin were purchased from Vector Laborato-
ries, Sigma and Santa Cruz, respectively. Rabbit polyclonal
antibodies against HDAC6 and alpha-tubulin were purchased
from Abcam. Rabbit polyclonal GFP antibody was purchased
from Invitrogen. Secondary antibodies, Alexa Fluor 680 goat anti-
mouse IgG and InfraRed Dye 800 goat anti-rabbit IgG, were
purchased from Invitrogen and Rockland, respectively.
Co-immunoprecipitation assays, pulldown assays and
Western blot
Cells were transfected using Lipofectamine 2000 (Invitrogen) in
OptiMEM (Gibco) for 48 hours. Cells were lysed and immuno-
precipitated (IP) as previously described [6]. For pulldown assays,
dysferlin-transfected cells were similarly lysed, and supernatants
were incubated with His-Select Nickel Affinity (Ni-NTA) Gel
(Sigma) in the presence of 20 mM Imidazole (Sigma) overnight at
4uC, washed with 50 mM Imidazole, and incubated with FLAG-
HDAC6-expressing cell extracts (similarly prepared), or with
wildtype murine testes homogenates (prepared as described [6]),
overnight at 4uC in IP buffer. Beads were washed with 50 mM
Imidazole and separated by SDS-PAGE. Proteins were transferred
onto PVDF membranes, blocked in Blocking buffer (3% Top-
Block (LubioScience) with 0.05% sodium azide (Sigma)), incubat-
ed overnight with the indicated antibodies in Blocking buffer plus
0.05% Tween-20 (Merck) and detected by Fluorimetric analysis
(Odyssey version 2.1.12). All experiments were performed in
triplicates. Densiometric analysis was performed using ImageJ
1.43 u (NIH, USA). Statistical analysis was performed using the
Student’s T-test with a significance level of at least 0.05.
Microtubule depolymerization and recovery assays
For microtubule depolymerization assays, cells were grown to
confluency and treated for 45 min with the indicated concentra-
tion of Nocodazole (Sigma) in growth media, or alternatively
incubated at 4uC for the indicated lengths of time. Cells were
washed, lysed and western blotted as described above. For
recovery experiments, cells were treated similarly, then Nocoda-
zole was replaced with fresh media and cells were incubated at
37uC, 5% CO2 for the indicated lengths of time. Cells were
washed, lysed and western blotted as described above. All
experiments were performed in triplicates. Densiometric analysis
was performed using ImageJ 1.43 u (NIH, USA). Statistical
analysis was performed using the Student’s T-test with a sig-
nificance level of at least 0.05.
Immunofluorescence assays
Cells were grown on matrigel-coated coverslips in growth media
or in differentiation media for four days to induce myotube
formation. Cells were fixed with 4% paraformadehyde (PFA) for
20 min, blocked 15 min in 2% fish skin gelatin, 1% normal goat
serum, 0.15% Triton X-100 in PBS and incubated for 1 hour at
room temperature with the indicated antibodies. Incubation with
relative number. (E) Desmin-stained myotubes were counted for their average number of nuclei and categorized by myotube length as in (D). * in (D)
and (E) indicates p,0.05, significantly different from mock-treated myotubes in the same category. ** indicates that no myotubes were observed in
the indicated category. (F) Absolute number of desmin-stained myotubes were counted and categorized by treatment regime. * indicates p,0.05,
significantly different from Mock-treated. Shown here are results for C2C12 cells; similar results were obtained for 134/04 cells (not shown).
doi:10.1371/journal.pone.0028563.g007
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PLoS ONE | www.plosone.org 10 December 2011 | Volume 6 | Issue 12 | e28563anti-FLAG antibodies was performed at 37uC for 2 hours. Cells
were captured on a LSM 710 inverted confocal microscope (Zeiss)
and analyzed using Zen 2009 LE software (Zeiss). All experiments
were performed in triplicates.
Myoblast differentiation assays
Cells were grown to 80% confluency then switched to
differentiation media (2% horse serum (Sigma) in DMEM). Cells
were treated with 7.5 uM Tubastatin A (BioVision, LubioScience)
either at the same time at media switch (Day 0 or D0), after
48 hours in differentiation media (Day 2 or D2) or after 72 hours
(Day 4 or D4). 24 hours later (Day 5), cells were lysed and western
blotted as described above, or fixed with 4% PFA for 20 min,
blocked 15 min in 2% fish skin gelatin, 1% normal goat serum,
0.15% Triton X-100 in PBS, then stained for desmin and DAPI.
Myotubes were imaged with a Leica DMI6000B fluorescence
microscope with the Volocity 5.2.0 software (Improvision Ltd) and
analyzed with AnalySIS
D 5.0 (Soft-imaging). All experiments were
performed in triplicates. Statistical analysis was performed using
the Student’s T-test with a significance level of at least 0.05.
Supporting Information
Table S1 Primers used for dysferlin C2 domain deletion
constructs. List of primers used to clone dysferlin C2 deletion
constructs from full-length dysferlin. Residues that were deleted
from each construct are indicated. Deletion of the C2 domains
coding region was performed by PCR mutagenesis using either the
single or double mutagenic primers approach (see Materials and
Methods).
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